Atlas Venture Life Science Advisors, LLC Replimune Group, Inc. Transaction History

Atlas Venture Life Science Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$17.09 - $27.91 $17.3 Million - $28.2 Million	-1,010,000 Reduced 32.49%	2,098,300 $57.1 Million
Q3 2022 Nov 09, 2022	SELL	$15.6 - $21.15 $1.58 Million - $2.14 Million	-101,327 Reduced 3.16%	3,108,300 $53.7 Million
Q4 2021 May 16, 2022	BUY	$25.43 - $34.25 $81.6 Million - $110 Million	3,209,627 New	3,209,627 $87 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $605M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Atlas Venture Life Science Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Atlas Venture Life Science Advisors, LLC with notifications on news.